Home
Scholarly Works
A phase II study of RO4929097 (RO), a...
Conference

A phase II study of RO4929097 (RO), a gamma-secretase inhibitor, in advanced platinum (Pt)-resistant (R) ovarian cancer (OC): A study of the PMH, Chicago, and California phase II consortia

Authors

Diaz-Padilla I; Clarke BA; Hirte HW; Welch S; Mackay H; Biagi JJ; Reedijk M; Weberpals JI; Fleming GF; Wang L

Volume

30

Publisher

AMER SOC CLINICAL ONCOLOGY

Publication Date

May 20, 2012

Name of conference

48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)

Conference place

Chicago, IL

Conference start date

June 1, 2012

Conference end date

June 6, 2012

Conference proceedings

JOURNAL OF CLINICAL ONCOLOGY

Issue

15

ISSN

0732-183X

Labels

Fields of Research (FoR)

Contact the Experts team